Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Review

Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent

Authors: Chenhui Zhou, Yi Huang, Sheng Nie, Shengjun Zhou, Xiang Gao, Gao Chen

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Fisetin, a natural flavonoid, possesses numerous biological activities that have been extensively studied in various diseases. When it comes to cancer, fisetin exhibits a range of biological effects, such as suppressing cell growth, triggering programmed cell death, reducing the formation of new blood vessels, protecting against oxidative stress, and inhibiting cell migration. Moreover, fisetin has the ability to enhance the effectiveness of chemotherapy. The anticancer properties of fisetin can be attributed to a diverse array of molecules and signaling pathways, including vascular endothelial growth factor (VEGF), mitogen-activated protein kinase (MAPK), nuclear factor-kappa B (NF-κB), PI3K/Akt/mTOR, and Nrf2/HO-1. Consequently, fisetin holds promise as a therapeutic agent for anticancer treatment. In this review, we place emphasis on the biological functions and various molecular targets of fisetin in anticancer therapy.
Literature
1.
Dey P, Kimmelman AC, DePinho RA. Metabolic codependencies in the tumor microenvironment. Cancer Discov. 2021;11(5):1067–81.PubMedPubMedCentral
2.
Tajan M, Vousden KH. Dietary approaches to cancer therapy. Cancer Cell. 2020;37(6):767–85.PubMed
3.
4.
5.
Syed DN, Adhami VM, Khan MI, Mukhtar H. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem. 2013;13(7):995–1001.PubMedPubMedCentral
6.
Khan H, Ullah H, Martorell M, Valdes SE, Belwal T, Tejada S, et al. Flavonoids nanoparticles in cancer: treatment, prevention and clinical prospects. Semin Cancer Biol. 2021;69:200–11.PubMed
7.
Khan N, Jajeh F, Eberhardt EL, Miller DD, Albrecht DM, Van Doorn R, et al. Fisetin and 5-fluorouracil: effective combination for PIK3CA-mutant colorectal cancer. Int J Cancer. 2019;145(11):3022–32.PubMedPubMedCentral
8.
9.
Yamaura K, Nelson AL, Nishimura H, Rutledge JC, Ravuri SK, Bahney C, et al. The effects of fisetin on bone and cartilage: a systematic review. Pharmacol Res. 2022;185: 106504.PubMed
10.
Farooqi AA, Naureen H, Zahid R, Youssef L, Attar R, Xu B. Cancer chemopreventive role of fisetin: regulation of cell signaling pathways in different cancers. Pharmacol Res. 2021;172: 105784.PubMed
11.
Chen L, Liu S, Tao Y. Regulating tumor suppressor genes: post-translational modifications. Signal Transduct Target Ther. 2020;5(1):90.PubMedPubMedCentral
12.
13.
Rahmani AH, Almatroudi A, Allemailem KS, Khan AA, Almatroodi SA. The potential role of fisetin, a flavonoid in cancer prevention and treatment. Molecules. 2022;27(24):9009.PubMedPubMedCentral
14.
Wang N, Yao F, Li K, Zhang L, Yin G, Du M, et al. Fisetin regulates astrocyte migration and proliferation in vitro. Int J Mol Med. 2017;39(4):783–90.PubMedPubMedCentral
15.
Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018;21(3):425–532.PubMedPubMedCentral
16.
Li T, Kang G, Wang T, Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 2018;16(1):687–702.PubMedPubMedCentral
17.
Uemura A, Fruttiger M, D’Amore PA, De Falco S, Joussen AM, Sennlaub F, et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res. 2021;84: 100954.PubMedPubMedCentral
18.
Kubina R, Krzykawski K, Kabala-Dzik A, Wojtyczka RD, Chodurek E, Dziedzic A. Fisetin, a potent anticancer flavonol exhibiting cytotoxic activity against neoplastic malignant cells and cancerous conditions: a scoping, comprehensive review. Nutrients. 2022;14(13):2604.PubMedPubMedCentral
19.
20.
Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, et al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updates. 2018;41:1–25.
21.
Fathi N, Rashidi G, Khodadadi A, Shahi S, Sharifi S. STAT3 and apoptosis challenges in cancer. Int J Biol Macromol. 2018;117:993–1001.PubMed
22.
Kashyap D, Garg VK, Tuli HS, Yerer MB, Sak K, Sharma AK, et al. Fisetin and quercetin: promising flavonoids with chemopreventive potential. Biomolecules. 2019;9(5):174.PubMedPubMedCentral
23.
Hassan SSU, Samanta S, Dash R, Karpinski TM, Habibi E, Sadiq A, et al. The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: focus on the role of oxidative stress. Front Pharmacol. 2022;13:1015835.PubMedPubMedCentral
24.
Wissler Gerdes EO, Zhu Y, Weigand BM, Tripathi U, Burns TC, Tchkonia T, et al. Cellular senescence in aging and age-related diseases: implications for neurodegenerative diseases. Int Rev Neurobiol. 2020;155:203–34.PubMedPubMedCentral
25.
Monasterio A, Urdaci MC, Pinchuk IV, Lopez-Moratalla N, Martinez-Irujo JJ. Flavonoids induce apoptosis in human leukemia U937 cells through caspase- and caspase-calpain-dependent pathways. Nutr Cancer. 2004;50(1):90–100.PubMed
26.
Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018;80:50–64.PubMed
27.
Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34(11):1675–99.PubMed
28.
29.
Afroze N, Pramodh S, Shafarin J, Bajbouj K, Hamad M, Sundaram MK, et al. Fisetin deters cell proliferation, induces apoptosis, alleviates oxidative stress and inflammation in human cancer cells, HeLa. Int J Mol Sci. 2022;23(3):1707.PubMedPubMedCentral
30.
Iside C, Scafuro M, Nebbioso A, Altucci L. SIRT1 activation by natural phytochemicals: an overview. Front Pharmacol. 2020;11:1225.PubMedPubMedCentral
31.
Hussain T, Al-Attas OS, Alamery S, Ahmed M, Odeibat HAM, Alrokayan S. The plant flavonoid, fisetin alleviates cigarette smoke-induced oxidative stress, and inflammation in Wistar rat lungs. J Food Biochem. 2019;43(8): e12962.PubMed
32.
Sahu BD, Kalvala AK, Koneru M, Mahesh Kumar J, Kuncha M, Rachamalla SS, et al. Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-kappaB activation and antioxidant defence. PLoS ONE. 2014;9(9): e105070.PubMedPubMedCentral
33.
Zhong Y, Yang L, Xiong F, He Y, Tang Y, Shi L, et al. Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc. Signal Transduct Target Ther. 2021;6(1):240.PubMedPubMedCentral
34.
Mierke CT. The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells. Rep Prog Phys. 2019;82(6): 064602.PubMed
35.
Pape J, Magdeldin T, Stamati K, Nyga A, Loizidou M, Emberton M, et al. Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma. Br J Cancer. 2020;123(7):1178–90.PubMedPubMedCentral
36.
de Gooijer MC, Guillen Navarro M, Bernards R, Wurdinger T, van Tellingen O. An experimenter’s guide to glioblastoma invasion pathways. Trends Mol Med. 2018;24(9):763–80.PubMed
37.
Alvarez-Elizondo MB, Weihs D. Breast cancer stem cells: mechanobiology reveals highly invasive cancer cell subpopulations. Cell Mol Life Sci. 2022;79(3):134.PubMed
38.
Xiao Y, Liu Y, Gao Z, Li X, Weng M, Shi C, et al. Fisetin inhibits the proliferation, migration and invasion of pancreatic cancer by targeting PI3K/AKT/mTOR signaling. Aging (Albany NY). 2021;13(22):24753–67.PubMed
39.
Mukhtar E, Adhami VM, Sechi M, Mukhtar H. Dietary flavonoid fisetin binds to beta-tubulin and disrupts microtubule dynamics in prostate cancer cells. Cancer Lett. 2015;367(2):173–83.PubMedPubMedCentral
40.
do Nascimento RP, Dos Santos BL, Amparo JAO, Soares JRP, da Silva KC, Santana MR, et al. Neuroimmunomodulatory properties of flavonoids and derivates: a potential action as adjuvants for the treatment of glioblastoma. Pharmaceutics. 2022;14(1):116.PubMedPubMedCentral
41.
Luond F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F, et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021;56(23):3203-3221 e11.PubMed
42.
McCabe EM, Rasmussen TP. lncRNA involvement in cancer stem cell function and epithelial–mesenchymal transitions. Semin Cancer Biol. 2021;75:38–48.PubMed
43.
Agraval H, Sharma JR, Prakash N, Yadav UCS. Fisetin suppresses cigarette smoke extract-induced epithelial to mesenchymal transition of airway epithelial cells through regulating COX-2/MMPs/beta-catenin pathway. Chem Biol Interact. 2022;351: 109771.PubMed
44.
Son S, Kim JH, Wang X, Zhang C, Yoon SA, Shin J, et al. Multifunctional sonosensitizers in sonodynamic cancer therapy. Chem Soc Rev. 2020;49(11):3244–61.PubMed
45.
Weingart SN, Zhang L, Sweeney M, Hassett M. Chemotherapy medication errors. Lancet Oncol. 2018;19(4):e191–9.PubMed
46.
47.
Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18(12):773–91.PubMed
48.
Chen YX, Wang CJ, Xiao DS, He BM, Li M, Yi XP, et al. eIF3a R803K mutation mediates chemotherapy resistance by inducing cellular senescence in small cell lung cancer. Pharmacol Res. 2021;174: 105934.PubMed
49.
Khozooei S, Lettau K, Barletta F, Jost T, Rebholz S, Veerappan S, et al. Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells. J Exp Clin Cancer Res. 2022;41(1):256.PubMedPubMedCentral
50.
Sabarwal A, van Rooyen JC, Caburet J, Avgenikos M, Dheeraj A, Ali M, et al. A novel 4’-brominated derivative of fisetin induces cell cycle arrest and apoptosis and inhibits EGFR/ERK1/2/STAT3 pathways in non-small-cell lung cancer without any adverse effects in mice. FASEB J. 2022;36(12): e22654.PubMed
51.
Tabasum S, Singh RP. Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition. Chem Biol Interact. 2019;303:14–21.PubMed
52.
Li S, Livingston MJ, Ma Z, Hu X, Wen L, Ding HF, et al. Tubular cell senescence promotes maladaptive kidney repair and chronic kidney disease after cisplatin nephrotoxicity. JCI Insight. 2023;8: e166643.PubMedPubMedCentral
53.
Ferreira de Oliveira JMP, Pacheco AR, Coutinho L, Oliveira H, Pinho S, Almeida L, et al. Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models. Arch Toxicol. 2018;92(3):1205–14.PubMed
54.
Shi YS, Li CB, Li XY, Wu J, Li Y, Fu X, et al. Fisetin attenuates metabolic dysfunction in mice challenged with a high-fructose diet. J Agric Food Chem. 2018;66(31):8291–8.PubMed
55.
Chen YP, Sivalingam K, Shibu MA, Peramaiyan R, Day CH, Shen CY, et al. Protective effect of Fisetin against angiotensin II-induced apoptosis by activation of IGF-IR-PI3K-Akt signaling in H9c2 cells and spontaneous hypertension rats. Phytomedicine. 2019;57:1–8.PubMed
56.
Sobierajska K, Ciszewski WM, Sacewicz-Hofman I, Niewiarowska J. Endothelial cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1234:71–86.PubMed
57.
Pulkkinen HH, Kiema M, Lappalainen JP, Toropainen A, Beter M, Tirronen A, et al. BMP6/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF. Angiogenesis. 2021;24(1):129–44.PubMed
58.
Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway. Int J Mol Sci. 2018;19(4):1232.PubMedPubMedCentral
59.
Ribatti D, Annese T, Tamma R. Controversial role of mast cells in breast cancer tumor progression and angiogenesis. Clin Breast Cancer. 2021;21(6):486–91.PubMed
60.
Trouillas J, Delgrange E, Wierinckx A, Vasiljevic A, Jouanneau E, Burman P, et al. Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours. Neuroendocrinology. 2019;109(1):70–6.PubMed
61.
Takahashi S, Bhattacharjee S, Ghosh S, Sugimoto N, Bhowmik S. Preferential targeting cancer-related i-motif DNAs by the plant flavonol fisetin for theranostics applications. Sci Rep. 2020;10(1):2504.PubMedPubMedCentral
62.
Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13(1):113.PubMedPubMedCentral
63.
Zhang M, Zhang S. Mitogen-activated protein kinase cascades in plant signaling. J Integr Plant Biol. 2022;64(2):301–41.PubMed
64.
Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37(4):543–50.PubMed
65.
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997–2007.PubMedPubMedCentral
66.
Fan J, Ren D, Wang J, Liu X, Zhang H, Wu M, et al. Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS/MAPK signaling pathway in vitro and in vivo. Cell Death Dis. 2020;11(2):126.PubMedPubMedCentral
67.
Lu H, Wang H, Huang G, Wang X, Bu X. Therapeutic targeting of mechanical stretch-induced FAK/ERK signaling by fisetin in hypertrophic scars. Eur J Pharmacol. 2022;932: 175228.PubMed
68.
Prem PN, Sivakumar B, Boovarahan SR, Kurian GA. Recent advances in potential of Fisetin in the management of myocardial ischemia-reperfusion injury-A systematic review. Phytomedicine. 2022;101: 154123.PubMed
69.
Yan W, Chen S, Zhao Y, Ye X. Fisetin inhibits the proliferation of gastric cancer cells and induces apoptosis through suppression of ERK 1/2 activation. Oncol Lett. 2018;15(6):8442–6.PubMedPubMedCentral
70.
Kammerud SC, Metge BJ, Elhamamsy AR, Weeks SE, Alsheikh HA, Mattheyses AL, et al. Novel role of the dietary flavonoid fisetin in suppressing rRNA biogenesis. Lab Invest. 2021;101(11):1439–48.PubMedPubMedCentral
71.
Adan A, Baran Y. The pleiotropic effects of fisetin and hesperetin on human acute promyelocytic leukemia cells are mediated through apoptosis, cell cycle arrest, and alterations in signaling networks. Tumour Biol. 2015;36(11):8973–84.PubMed
72.
Taniguchi K, Karin M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–24.PubMed
73.
Ren C, Han X, Lu C, Yang T, Qiao P, Sun Y, et al. Ubiquitination of NF-kappaB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance. Cell Death Differ. 2022;29(2):381–92.PubMed
74.
Patel M, Horgan PG, McMillan DC, Edwards J. NF-kappaB pathways in the development and progression of colorectal cancer. Transl Res. 2018;197:43–56.PubMed
75.
Song L, Chen X, Mi L, Liu C, Zhu S, Yang T, et al. Icariin-induced inhibition of SIRT6/NF-kappaB triggers redox mediated apoptosis and enhances anti-tumor immunity in triple-negative breast cancer. Cancer Sci. 2020;111(11):4242–56.PubMedPubMedCentral
76.
Wang Y, Zhang J, Li YJ, Yu NN, Liu WT, Liang JZ, et al. MEST promotes lung cancer invasion and metastasis by interacting with VCP to activate NF-kappaB signaling. J Exp Clin Cancer Res. 2021;40(1):301.PubMedPubMedCentral
77.
Wang R, Ma Y, Zhan S, Zhang G, Cao L, Zhang X, et al. B7–H3 promotes colorectal cancer angiogenesis through activating the NF-kappaB pathway to induce VEGFA expression. Cell Death Dis. 2020;11(1):55.PubMedPubMedCentral
78.
Gu P, Zhang M, Zhu J, He X, Yang D. Suppression of CDCA3 inhibits prostate cancer progression via NF-kappaB/cyclin D1 signaling inactivation and p21 accumulation. Oncol Rep. 2022;47(2):1–10.
79.
Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, et al. CECR2 drives breast cancer metastasis by promoting NF-kappaB signaling and macrophage-mediated immune suppression. Sci Transl Med. 2022;14(630):eabf5473.PubMedPubMedCentral
80.
Wan X, Guan S, Hou Y, Qin Y, Zeng H, Yang L, et al. FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts. Theranostics. 2021;11(10):4975–91.PubMedPubMedCentral
81.
Bai Y, Lam HC, Lei X. Dissecting programmed cell death with small molecules. Acc Chem Res. 2020;53(5):1034–45.PubMed
82.
Ren Q, Guo F, Tao S, Huang R, Ma L, Fu P. Flavonoid fisetin alleviates kidney inflammation and apoptosis via inhibiting Src-mediated NF-kappaB p65 and MAPK signaling pathways in septic AKI mice. Biomed Pharmacother. 2020;122: 109772.PubMed
83.
Molagoda IMN, Jayasingha J, Choi YH, Jayasooriya R, Kang CH, Kim GY. Fisetin inhibits lipopolysaccharide-induced inflammatory response by activating beta-catenin, leading to a decrease in endotoxic shock. Sci Rep. 2021;11(1):8377.PubMedPubMedCentral
84.
Khan H, Ullah H, Castilho P, Gomila AS, D’Onofrio G, Filosa R, et al. Targeting NF-kappaB signaling pathway in cancer by dietary polyphenols. Crit Rev Food Sci Nutr. 2020;60(16):2790–800.PubMed
85.
Pal HC, Sharma S, Strickland LR, Katiyar SK, Ballestas ME, Athar M, et al. Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFkappaB signaling pathways. PLoS ONE. 2014;9(1): e86338.PubMedPubMedCentral
86.
Li J, Qu W, Cheng Y, Sun Y, Jiang Y, Zou T, et al. The inhibitory effect of intravesical fisetin against bladder cancer by induction of p53 and down-regulation of NF-kappa B pathways in a rat bladder carcinogenesis model. Basic Clin Pharmacol Toxicol. 2014;115(4):321–9.PubMed
87.
Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125–32.PubMed
88.
Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol. 2019;59:147–60.PubMed
89.
Qian J, LeSavage BL, Hubka KM, Ma C, Natarajan S, Eggold JT, et al. Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling. J Clin Invest. 2021;131(16): e146186.PubMedPubMedCentral
90.
Stefani C, Miricescu D, Stanescu S II, Nica RI, Greabu M, Totan AR, et al. Growth factors, PI3K/AKT/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now? Int J Mol Sci. 2021;22(19):10260.PubMedPubMedCentral
91.
Zhou J, Jiang YY, Chen H, Wu YC, Zhang L. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. Cell Prolif. 2020;53(2): e12739.PubMed
92.
Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8.PubMedPubMedCentral
93.
Ma Z, Lou S, Jiang Z. PHLDA2 regulates EMT and autophagy in colorectal cancer via the PI3K/AKT signaling pathway. Aging (Albany NY). 2020;12(9):7985–8000.PubMed
94.
Chen K, Zhu P, Chen W, Luo K, Shi XJ, Zhai W. Melatonin inhibits proliferation, migration, and invasion by inducing ROS-mediated apoptosis via suppression of the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells. Aging (Albany NY). 2021;13(18):22502–15.PubMed
95.
Yang J, Mo J, Dai J, Ye C, Cen W, Zheng X, et al. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death Dis. 2021;12(11):1079.PubMedPubMedCentral
96.
Chakraborty S, Balan M, Flynn E, Zurakowski D, Choueiri TK, Pal S. Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. Oncogenesis. 2019;8(2):7.PubMedPubMedCentral
97.
Zhang YY, Yao YD, Chen F, Guo X, Kang JL, Huang YF, et al. (9S,13R)-12-oxo-phytodienoic acid attenuates inflammation by inhibiting mPGES-1 and modulating macrophage polarization via NF-kappaB and Nrf2/HO-1 pathways. Pharmacol Res. 2022;182: 106310.PubMed
98.
Lou Y, Guo Z, Zhu Y, Kong M, Zhang R, Lu L, et al. Houttuynia cordata Thunb. and its bioactive compound 2-undecanone significantly suppress benzo(a)pyrene-induced lung tumorigenesis by activating the Nrf2-HO-1/NQO-1 signaling pathway. J Exp Clin Cancer Res. 2019;38(1):242.PubMedPubMedCentral
99.
Li D, Liu X, Pi W, Zhang Y, Yu L, Xu C, et al. Fisetin attenuates doxorubicin-induced cardiomyopathy in vivo and in vitro by inhibiting ferroptosis through SIRT1/Nrf2 signaling pathway activation. Front Pharmacol. 2021;12: 808480.PubMed
100.
Zhang L, Wang H, Zhou Y, Zhu Y, Fei M. Fisetin alleviates oxidative stress after traumatic brain injury via the Nrf2-ARE pathway. Neurochem Int. 2018;118:304–13.PubMed
101.
Park C, Noh JS, Jung Y, Leem SH, Hyun JW, Chang YC, et al. Fisetin attenuated oxidative stress-induced cellular damage in ARPE-19 human retinal pigment epithelial cells through Nrf2-mediated activation of heme oxygenase-1. Front Pharmacol. 2022;13: 927898.PubMedPubMedCentral
102.
Tsai CF, Chen JH, Chang CN, Lu DY, Chang PC, Wang SL, et al. Fisetin inhibits cell migration via inducing HO-1 and reducing MMPs expression in breast cancer cell lines. Food Chem Toxicol. 2018;120:528–35.PubMed
103.
Moghassemi S, Dadashzadeh A, Azevedo RB, Amorim CA. Nanoemulsion applications in photodynamic therapy. J Control Release. 2022;351:164–73.PubMed
104.
Vishwas S, Singh SK, Gulati M, Awasthi A, Khursheed R, Corrie L, et al. Harnessing the therapeutic potential of fisetin and its nanoparticles: journey so far and road ahead. Chem Biol Interact. 2022;356: 109869.PubMed
105.
Dutta S, Moses JA, Anandharamakrishnan C. Encapsulation of nutraceutical ingredients in liposomes and their potential for cancer treatment. Nutr Cancer. 2018;70(8):1184–98.PubMed
106.
Onorati AV, Dyczynski M, Ojha R, Amaravadi RK. Targeting autophagy in cancer. Cancer. 2018;124(16):3307–18.PubMed
107.
Metadata
Title
Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
Authors
Chenhui Zhou
Yi Huang
Sheng Nie
Shengjun Zhou
Xiang Gao
Gao Chen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01271-8

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Review

Research trends and hotspots evolution of cardiac amyloidosis: a bibliometric analysis from 2000 to 2022

Research

Amoxicillin-induced aseptic meningitis: clinical features, diagnosis and management

Research

Declined plasma microfibrillar-associated protein 4 levels in acute coronary syndrome

Research

Remimazolam tosylate's long-term sedative properties in ICU patients on mechanical ventilation: effectiveness and safety

Review

SIgA in various pulmonary diseases

Review

Mesenchymal stem cells-derived exosomes: novel carriers for nanoparticle to combat cancer